This study of 30 patients with hyp erplastic rhinosinusitis reveals that the maj or determinant of the success or fa ilure ofconservative therapy is the p resence or abse nce ofintranasal polyposis. When polyposis is conf irmed both clinically and radiograp hically, surgical interve ntion appears to be the rational way to handl e most cases. When intranasa l polyps are not pr esent, an aggressiv e medical regimen is calledfo r, one that incl udes a short-term, lowdose oral corticosteroid and an ant ibiotic, along with periodic radiographic assessment. Regardl ess of how much disease is seen on computed tomograph y, if it does not also detect intranasal polyps or masses, the potential fo r cleari ng with conservative therapy is extremely high.
Introduction
A stag ing sys tem based on co mputed tom ograph y (CT) he lps the physici an determine the app rop riate ther apy for patient s with nasal and paranasal si nus co mplaints.':"Th e prime moti ve behind the developmen t of such a classi fication wa s to seg rega te those patien ts who requ ire surgery fro m those who ca n be man aged medi cally. Staging is parti cul arly imp ort ant to stage I and III patient s, who acco unt for up to 90% of all patients who require CT imaging.I Patient s in these two gro ups usually have mucosal di sease (unilateral or bilateral ) or structural abnormalit ies, bu t not nasal polyps or other nasal masses.
Thi s repo rt is based on our evaluation of 30 stage I and III patient s wh o were deem ed to be potential candidates for surgery. Th ese patient s had all been man aged wi th aggre ssive medical therapy, including one or two short co urses of an oral corticos teroid in add itio n to an antibiotic (table I) 
Materials and Methods
We studied 30 patients who had present ed with paran asal and nasal compl aint s during a 4-year peri od fro m 1994 through 1997 . To be included in this study, patient s we re required to meet four separate criter ia (table 2). All patient s had und ergone CT of their pa ra nasal sinuses and we re subsequently cl assified as eithe r stage I or III, accord ing to prev iou sly publ ished cri teria. All were considered to be pot enti al candida tes for surgery by either the author or by another otolaryngo log ist. Most of these Figure 1 . Top row: CT of a patient with advanced bilateral stage III disease (left) shows complete clearing after two courses of an oral corticosteroid and an antibiotic (right) . Middle row: CT of a patient with predominantly unilateral disease (left). This patient was initially classifi ed as stage I, but later upgraded to stage III. Note complete clearing (right) after 2 months of oral corticosteroid and antibiotic therapy. Bo ttom row: CT of a patient with advanced stage III disease (left) who had been on continuous antibiotic therapy for 2 months prior to starting oral corticosteroid therap y. Medical therapy resulted in a complete clinical resolution and significant (but not complete) radiographic clearing (right).
patie nts had alread y been treated with at least one co urse of an antibi otic, plus an antihistamine, a nasal decongestant , or a topi cal cor ticos teroi d. No ne of these patient s had been on an oral cor ticos teroid prior to bein g staged and started on a more aggressive medical reg imen. Each patient was prescribed a 6day course of an oral cor ticosteroid (Medrol Dosepak); a beta-lactam ase antibiotic was given concomitant ly to patients who were not allergic to peni cilli n. A n imme d ia te rep eat co urse of both dru gs was reco mmended and usually followed forthose patient s who did not full y respon d.' Dur ing drug treatment , patients were instructed to noti fy their physic ian if they became febril e or if they noticed any other cha nges in symptoma tology . Upon the compl etion of thi s course of agg ressi ve medical therapy , patient s were mai ntained on either a corticostero id na sal spray or a nonsedating antihistamine until they underwent a seco nd CT.
CT Results
The repeat CT was performed an average of 3 months followi ng the completion of stero id therapy (for a variety of reason s, the range varied significantly, from 2 weeks to 2 years). Four pati ents wh o were in iti all y thought to fall into the stage 1 category were later upgraded to stage III because CT had revealed that almos t all of them had some degree of mucosal disease or structural abnormality on the oppos ite side. Thi s recl assification attests to the sensitivity of the CT scanners at our disposa l.
According to other staging systems, 16 of the 30 patient s (53%) in this study would have been considered to have more adva nced disease than they actually had .' > The CTs of these 16 patients showe d a compl ete opac ification of two or more sinus complexes on one or both sides (figure I). Four other patient s who had only mild or early mucosal changes, prim aril y in the ethmoids, were nonetheless considered to be potent ial surgical candidates because they had a lower respiratory disorder, such as chronic bron-chitis, asthma, emphyse ma, or bronch iectasis (figure 2). The rema ining 10 patient s had less-than-severe disease, which was mani fested by a partial opacification of one or more sinuses and by various degrees of mucosal thickening and eve n air-fluid interfaces (figure 3). objective modality like CT ca n help monitor the performa nce of these drugs. A significant numb er of stagi ng systems has been proposed and compared, but these sys tems appear to be more co nce rned with the outcomes of surgery than the need for surgery.'> Most of the stag ing sys tems rely on numerous fac tors, suc h as mucosal thickening, opacification/partia l opacification, the number ofsinuses involved, unilaterality/bilatera lity, etc. For this report, the aut hor originally cons idered proposing a staging syste m that was based on only two fac tors : unilaterality/bilatera lity and the prese nce/absence of nasal po lyps, clinically or radiogra phically. But upon furt her study, it became apparent that mak ing a dist inction between un ilateral and bilatera l disease is so mew hat redundant in ligh t of the se nsitivity of CT and the fac t that almos t all patients have so me degree of bilatera l structural abnormality . We are, then ,
Discussion
The indications for paranasal sinus surgery have always bee n controversia l." In 1985, the issue seemed to be part ially resolved with the introd uction of nasal endoscopes and a new emphasis on CT scan ning. See mingly overnight, surg ical proced ures that were once thoug ht to be too risky beca me com monp lace, and the cri teria for surgery significantly ex panded. CT not only detected ethmoid and sphe noid mucosal disease, it also revealed struc tura l abnor ma lities that were not previous ly ap prec iated .
Hyperplastic rhinosi nusit is is bes t diagnosed and classified when the presence or abse nce of nasal polyps and other intranasal lesions seen on clinical exa mination are confirmed by CT. When pol yposis is not present, there is a high likel ihood that the problem will be resolved with aggressive medical therapy.
The use of small-dose, sho rt-term ora l cor ticosteroid therapy in the management of paranasal sinus prob lems is con troversial. Th ere seems to be an inordinate reluctance on the part of most physicians, including oto laryngologistshead and neck surgeons, to accept this type of reg imen, especially in light of the fact that the prude nt use of an
Results
Re peat CT revealed that the aggressive steroid regimen resu lted in significant clear ing in 25 of the 30 patients, including clearing in all 16 of those pat ients who wou ld have been misclassified under other staging sys te ms as hav ing advanced disease (tab le 3). Most patients improved both clin ically and radiographica lly
The 5 patients who did not improve were advised to undergo surgery. Only 2 of the 5 followed this recommendation. One of the 2 had a unilateral mucopyocele of the eth moid sinus that was ca using a rapid obstruction of this sinus co mplex, and the other contin ued to experience repeated episodes of chro nic asthmatic bronch itis, whic h did not resol ve until his sin uses were decompressed.
Th e 25 patie nts who were sig nifican tly impro ved were advised to use a corticosteroid nasal spray dai ly for at least I yea r. As of Jan. I, 1999, no ne of the 25 patien ts who experienced a sig nifica nt remission appears to have rela psed . Table 3 . Results of aggressive treatment of 30 patients left with one parameter: the presence or abse nce of intranasal polyposis or other types of nasal masses. The status of these lesions alon e is sufficient to distingui sh patients who will probably respond to aggre ssive conservative therapy from patient s who will probably be refractory to it (stages II and IV). It seems import ant to point out that aggressive medical therapy does not mean ju st a 1-or 2-week course of a topical steroid and an antibiotic . Trul y aggressive therapy calls for an oral corticosteroi d and an anti biotic (with or without an antihistamine), plus a decongestant or a nasal spray . For a staging system to succeed, and it seems vitally important that one should, it must be more simplified than the one s currently in use. It is not rational to comp are the outcomes of surgical patient s with those of medically treated patients who have comparable findings on e T.
It may be prud ent for the Rhinosinusitis Ta sk Force of the American Academy of Otolaryngology-Head and Neck Surgery to exa mine more closely what constitutes appropriate conservative therapy and to learn what physicians around the country are prescribing. It is difficult to be critical of a group of professionals that has spent so much time formulating a standardized policy, but they ought to be rece ptive to considering any flaws that exist in their work. Afterdaily oral dosesof 750mglkg (mice)and 250mglkg (rats) were administered for upto 2 years, therewas noevidence that ciprofloxacin had any carcinogenic or tumorigenic effectsin these species. Nolong term studies of CIPRO' HC OTIC suspensi on havebeen performed to evaluatecarci nogeni c potential. Fertilitystudies performed in rats at oral doses of ciprofloxacin up to 100 mglkg/day revealed no evidenceof impairment. This would beover 1000 times themaximum recommendedclinical dose of ototopical ciprofloxacin based upon body surface area, assuming total absorption of ciprofloxacin from the ear of a patient treated wi th CI PRO ' HCOTICtwice per day. Longterm studieshave notbeen performed to evaluate thecarcinogenicpotential orthe effect onfertility of topical hydrocortisone. Mutagenicitystudies with hydrocortisonewerenegative. Pregnancy: Teratogenic Effects. Pregnancy Category C: Reproductionstudies have been perf ormed in rats and mice using oral doses of upto 100 mglkg and IV doses upto 30 mglkg andhave reveal ed noevidence of harm to the fetus asa resul t of ci prof loxacin. In rabbits, ciprofloxacin (30and 100 mglkg orally) produced gastrointestinal di sturbances resulting in maternal weight loss and an increasedincidence of abortion, but no teratogenicitywasobserved at either dose. After intravenousadministrationof dosesupto20 mg lkg, no maternal toxicity was produced in the rabbi t, and no embryotoxicity or teratogenicity was observed. Corticosteroids aregenerall y teratogenicin laboratoryanimalswhen administered systemicallyat rel ativel y low dosage levels. The morepotent corticosteroids have been shownto beteratogenic afterdermal application in laboratoryanimals. Animal reproductionstudieshavenot beenconductedwithCIPRO' HC OTIC. Noadequateandwell controlledstudies have beenperformedin pregnant women. Caution should beexercised when CIPRO' HC OTICis used by a preg nant woman. Nursing Mothers: Ciprofloxacin is excreted in human milkwith systemic use. It is not known whether ciprofloxacin is excreted in human milkfollowingtopical otic administration. Because of the pot ential for serious adverse reactions in nursing infants, a decision should be made whether to discont inue nursing or to discontinuethedrug, takingintoaccountthe importance of thedrugto the mother. Pediatric use: Thesaf ety and effi cacy of CIPRO' HC OTIC have been established in pediatric patients 2 years and older (131 pat ient s) in adequate and well-controlled clinical trials. Although nodat aare avai lable onpat ient s less thanage2years, therearenoknownsafety concernsor differences in thedisease process inthis populationwhich would preclude use of this product in pat ient s oneyear andolder. See DOSAGE AND ADMINISTRATION.
ADVERSE REACTIONS
In Phase3clinical trials, atotal of564 pat ients weretreatedwithCIPRO' HC OTIC. Adverseevents wi that leastremote relationshipto treatment included headache (1.2%) and pruritus (0.4%). The following treatment-related adverse events were each reported in a single patient migraine, hypesthesia, paresthesia, fungal dermatitis,cough, rash, urticaria, and alopecia. NDC 0065·8531-10 CIPRO' is a registeredtrademark of Bayer AG. Li censed by BayerAG Manufactured by Bayer Corporation Rx Onl y U.S. Pat.Nos. 4,670,444; 4,844,902; 5,843,930; and Pat. Pending. Revised January, 1999 CHCOB-0199
